Brief: Immuno-Oncology Company Portage Biotech Completes Monetization of Intensity Therapeutics Shares
March 26 (Reuters) - Portage Biotech:
* PORTAGE BIOTECH COMPLETES MONETIZATION OF INTENSITY
THERAPEUTICS
(INTS) SHARES
* PORTAGE BIOTECH INC - COMPANY WILL USE PROCEEDS TO FURTHER
FUND
ITS PORT-6 PHASE 1A PORTION OF ADPORT-601 TRIAL
Source text for Eikon: ID:nGNXb9VZb1
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing